Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06D ANTI-DEMENTIA DRUGS
N06DA Anticholinesterases
N06DA03 Rivastigmine
D03822 Rivastigmine (JAN/USP/INN)
USP drug classification [BR:br08302]
Antidementia Agents
Cholinesterase Inhibitors
Rivastigmine
D03822 Rivastigmine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D03822 Rivastigmine (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00984 Rivastigmine
D03822 Rivastigmine
DG01594 Butyrylcholinesterase inhibitor
DG00984 Rivastigmine
D03822 Rivastigmine
DG01968 Antidementia agent
DG00984 Rivastigmine
D03822 Rivastigmine
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Carboxylic-ester hydrolases
ACHE
D03822 Rivastigmine (JAN/USP/INN)
BCHE
D03822 Rivastigmine (JAN/USP/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03822
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03822